肿瘤基础与临床
腫瘤基礎與臨床
종류기출여림상
JOURNAL OF BASIC AND CLINICAL ONCOLOGY
2015年
2期
150-153
,共4页
肺癌%化疗%凝血功能%纤溶功能%血小板参数
肺癌%化療%凝血功能%纖溶功能%血小闆參數
폐암%화료%응혈공능%섬용공능%혈소판삼수
lung cancer%chemotherapy%coagulation function%fibrinolysis function%platelet parameters
目的:研究肺癌患者化疗前后凝血、纤溶功能及血小板参数的变化及其临床意义。方法56例肺癌患者肺癌患者化疗前后凝血、纤溶功能及血小板参数的变化被检测,并以56例健康体检者作为对照。结果肺癌患者血浆纤维蛋白原、血小板计数和血小板体积分布宽度分别为(4.31±0.75)g·L-1、(287.41±97.56)×109·L-1和16.01±2.86 fl,健康体检者分别为(3.19±0.46)g·L-1、(205.62±51.97)×109·L-1和(15.12±1.57)fl,比较差异均有统计学意义( P均<0.05)。化疗后肺癌患者凝血酶原时间由化疗前的(11.35±0.86)s减少为(10.21±0.65)s,血小板计数由(287.41±97.56)×109·L-1减少为(207.05
目的:研究肺癌患者化療前後凝血、纖溶功能及血小闆參數的變化及其臨床意義。方法56例肺癌患者肺癌患者化療前後凝血、纖溶功能及血小闆參數的變化被檢測,併以56例健康體檢者作為對照。結果肺癌患者血漿纖維蛋白原、血小闆計數和血小闆體積分佈寬度分彆為(4.31±0.75)g·L-1、(287.41±97.56)×109·L-1和16.01±2.86 fl,健康體檢者分彆為(3.19±0.46)g·L-1、(205.62±51.97)×109·L-1和(15.12±1.57)fl,比較差異均有統計學意義( P均<0.05)。化療後肺癌患者凝血酶原時間由化療前的(11.35±0.86)s減少為(10.21±0.65)s,血小闆計數由(287.41±97.56)×109·L-1減少為(207.05
목적:연구폐암환자화료전후응혈、섬용공능급혈소판삼수적변화급기림상의의。방법56례폐암환자폐암환자화료전후응혈、섬용공능급혈소판삼수적변화피검측,병이56례건강체검자작위대조。결과폐암환자혈장섬유단백원、혈소판계수화혈소판체적분포관도분별위(4.31±0.75)g·L-1、(287.41±97.56)×109·L-1화16.01±2.86 fl,건강체검자분별위(3.19±0.46)g·L-1、(205.62±51.97)×109·L-1화(15.12±1.57)fl,비교차이균유통계학의의( P균<0.05)。화료후폐암환자응혈매원시간유화료전적(11.35±0.86)s감소위(10.21±0.65)s,혈소판계수유(287.41±97.56)×109·L-1감소위(207.05
Objective To research the changes of coagulation,fibrinolysis function and platelet parameters of pa-tients with lung cancer and their clinical significance. Methods The changes of coagulation,fibrinolysis function and platelet parameters of the 56 patients with lung cancer were detected before and after treatment,and those of the healthy volunteers were detected too. Results The fibrinogen,platelets and platelet distribution width of the patients with lung cancer were(4. 31 ± 0. 75)g·L-1 ,(287. 41 ± 97. 56)× 109 ·L-1 and(16. 01 ± 2. 86)fl;those of the healthy volunteers were(3.19±0.46)g·L-1,(205.62 ±51.97)×109·L-1 and(15.12 ±1.57)fl(P<0. 05). After the chemotherapy,the prothrombin time of patients with lung cancer decreased from(11. 35 ± 0. 86)s to(10.21 ± 0. 65)s,the platelets decreased from(287. 41 ± 97. 56)× 109 ·L-1 to(207. 05 ± 81. 36)× 109·L-1,the hemoglobin decreased from(125.79 ±31.08)g·L-1 to(108.20 ±25.74)g·L-1(P<0.05). Conclusion The chemotherapy can induce the changes of coagulation and fibrinolysis function of the patients with lung cancer.